Clinical Trial Update: A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis [Phase 4]

View source ↗

Summary

This multicenter, open-label Phase IIIb/IV trial evaluates subcutaneously administered Raptiva (efalizumab) for adults with moderate to severe plaque psoriasis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Candidates for Systemic Therapy for Psoriasis, Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2018-04-03